Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

ATS Medical Reports Use of Recently Approved Heart Valve

publication date: Apr 21, 2010
ATS Medical reported the first commercial implant of the ATS 3f® Aortic Bioprosthesis, a tissue valve, was completed recently at Fu Wai Hospital in Beijing, China. ATS Medical, of Plymouth, Minnesota, received SFDA approval of the valve last month. ATS Medical maintains an office in Shanghai. The ATS 3f Aortic Bioprosthesis is a stentless pericardial aortic tissue valve that is designed to function like a native valve. More details...

Stock Symbol: (NSDQ: ATSI)


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here